Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) had its target price boosted by stock analysts at Barclays from $40.00 to $42.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price would indicate a potential upside of 15.14% from the stock’s current price.
Several other equities analysts have also recently commented on TEVA. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday, July 28th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $42.22.
Read Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Price Performance
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%.The company had revenue of $4.14 billion for the quarter. Research analysts predict that Teva Pharmaceutical Industries will post 1.96 earnings per share for the current year.
Insiders Place Their Bets
In related news, EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the completion of the transaction, the executive vice president owned 65,621 shares of the company’s stock, valued at $2,237,676.10. This represents a 61.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 259,831 shares of company stock valued at $9,091,659 over the last quarter. Insiders own 0.54% of the company’s stock.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
A number of institutional investors have recently added to or reduced their stakes in the stock. Victrix Investment Advisors raised its holdings in shares of Teva Pharmaceutical Industries by 9.5% in the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company’s stock worth $266,000 after buying an additional 681 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Teva Pharmaceutical Industries by 128.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock valued at $103,538,000 after buying an additional 1,716,315 shares in the last quarter. GAMMA Investing LLC boosted its stake in Teva Pharmaceutical Industries by 19.6% in the 2nd quarter. GAMMA Investing LLC now owns 11,361 shares of the company’s stock valued at $385,000 after buying an additional 1,859 shares in the last quarter. Versant Capital Management Inc grew its position in Teva Pharmaceutical Industries by 15.8% in the second quarter. Versant Capital Management Inc now owns 10,265 shares of the company’s stock valued at $348,000 after acquiring an additional 1,399 shares during the period. Finally, CX Institutional bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Further Reading
- Five stocks we like better than Teva Pharmaceutical Industries
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
